SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 10.3% – Still a Buy?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) rose 10.3% during trading on Monday . The company traded as high as $3.76 and last traded at $3.8160. Approximately 4,401,928 shares were traded during trading, a decline of 76% from the average daily volume of 18,068,063 shares. The stock had previously closed at $3.46.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.00.

SELLAS Life Sciences Group Stock Performance

The company has a market capitalization of $585.44 million, a PE ratio of -14.68 and a beta of 2.26. The company’s fifty day moving average is $2.25 and its 200-day moving average is $1.98.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. On average, sell-side analysts expect that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other SELLAS Life Sciences Group news, Director Katherine Bach Kalin purchased 63,400 shares of the business’s stock in a transaction on Wednesday, November 19th. The stock was acquired at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the purchase, the director owned 104,400 shares of the company’s stock, valued at approximately $165,996. This represents a 154.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Several large investors have recently made changes to their positions in the business. Axxcess Wealth Management LLC bought a new stake in SELLAS Life Sciences Group during the 3rd quarter valued at approximately $26,000. BNP Paribas Financial Markets grew its holdings in SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after buying an additional 9,299 shares in the last quarter. Blair William & Co. IL bought a new stake in shares of SELLAS Life Sciences Group during the second quarter valued at approximately $35,000. ProShare Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group in the second quarter worth $43,000. Finally, Sei Investments Co. bought a new position in shares of SELLAS Life Sciences Group during the third quarter worth $43,000. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.